Loading...

ATYR ATYR PHARMA INC Delisting Actions 8-K Filing

TYR

TYR

ATYR PHARMA INC

(ATYR)

2025 8-K

Financial Results Announced

Clinical Update

Financial Results Update

Delisting Notice

Financial Results

Phase 3 Study Results

Financial Statements

Financial Statements

Financial Statements

Stock Option Plans

Financial Results

Share Offering Update

Director Appointment

Financial Results

Financial Results

Clinical Trial Enrollment C...

Annual Meeting Approval

Earnings Reports

Earnings Reports

Financial Results Announcement

Investor Conferences

Presentation of Study Results

Financial Results Announcement

Annual Meeting Approval

Financial Results Announcement

Disinvestment of Assets

Financial Results Announcement

Public Offering

Phase 3 Study Milestone

External Links:

aTyr Pharma Inc received a Nasdaq deficiency notice on December 4, 2025, indicating that its stock price has been below $1.00 for the past 30 days. The company has until June 2, 2026, to regain compliance; if not, it may face delisting.

AI Assistant

ATYR PHARMA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.